NO20084579L - Procedure for Vaccination of Individuals Receiving Immunomodulatory Therapy - Google Patents
Procedure for Vaccination of Individuals Receiving Immunomodulatory TherapyInfo
- Publication number
- NO20084579L NO20084579L NO20084579A NO20084579A NO20084579L NO 20084579 L NO20084579 L NO 20084579L NO 20084579 A NO20084579 A NO 20084579A NO 20084579 A NO20084579 A NO 20084579A NO 20084579 L NO20084579 L NO 20084579L
- Authority
- NO
- Norway
- Prior art keywords
- vaccination
- procedure
- immunomodulatory therapy
- individuals receiving
- receiving immunomodulatory
- Prior art date
Links
- 230000002519 immonomodulatory effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 238000002255 vaccination Methods 0.000 title 1
- 208000026278 immune system disease Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 abstract 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 208000025095 immunoproliferative disease Diseases 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
SAMMENDRAG Foreliggende oppfinnelse angår metoder for vaksinering av individer som mottar immunmodulerende terapi, så som oppløselige CTLA4-molekyler, for behandling av immunsystem-sykdommer mediert av T-celle interaksjoner med B7-positive celler omfattende, men ikke begrenset til, autoimmune sykdommer, immunoproliferative sykdommer og immunlidelser forbundet med transplantasjon.SUMMARY OF THE INVENTION The present invention relates to methods for vaccinating individuals receiving immunomodulatory therapy, such as soluble CTLA4 molecules, for the treatment of immune system diseases mediated by T-cell interactions with B7-positive cells including, but not limited to, autoimmune diseases, immunoproliferative diseases. and immune disorders associated with transplantation.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79998106P | 2006-05-12 | 2006-05-12 | |
US84807806P | 2006-09-28 | 2006-09-28 | |
US11/800,860 US7528111B2 (en) | 2006-05-12 | 2007-05-08 | Method of vaccinating subjects receiving immune modulating therapy |
PCT/US2007/068631 WO2007134147A2 (en) | 2006-05-12 | 2007-05-10 | Method of vaccinating subjects receiving immune modulating therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20084579L true NO20084579L (en) | 2008-12-03 |
Family
ID=38694690
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20084579A NO20084579L (en) | 2006-05-12 | 2008-11-03 | Procedure for Vaccination of Individuals Receiving Immunomodulatory Therapy |
Country Status (8)
Country | Link |
---|---|
US (1) | US7528111B2 (en) |
EP (1) | EP2018181A2 (en) |
JP (1) | JP2009536968A (en) |
AR (1) | AR060897A1 (en) |
NO (1) | NO20084579L (en) |
PE (1) | PE20080092A1 (en) |
TW (1) | TW200812612A (en) |
WO (1) | WO2007134147A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7915222B2 (en) | 2008-05-05 | 2011-03-29 | Bristol-Myers Squibb Company | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
AU2012251919B2 (en) | 2011-01-19 | 2016-12-15 | Ferrumax Pharmaceuticals, Inc. | Compositions for regulating iron homeostasis and methods of using same |
KR20150033703A (en) * | 2012-06-27 | 2015-04-01 | 오르반 바이오테크 엘엘씨 | CTLA4 fusion proteins for the treatment of diabetes |
GB2523399B (en) | 2014-02-25 | 2019-03-13 | Orban Tihamer | A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2110518C (en) | 1991-06-27 | 2007-05-22 | Peter S. Linsley | Ctla4 receptor, fusion proteins containing it and uses thereof |
US6090914A (en) | 1991-06-27 | 2000-07-18 | Bristol-Myers Squibb Company | CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
US5773253A (en) | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
MXPA02012603A (en) | 2000-07-03 | 2003-05-14 | Squibb Bristol Myers Co | Methods for treating rheumatic diseases using a soluble ctla4 molecule. |
KR101235484B1 (en) | 2005-04-06 | 2013-02-22 | 브리스톨-마이어스 스큅 컴퍼니 | Methods for Treating Immune Disorders Associated with Graft Transplantaton with Soluble CTLA4 Mutant Molecules |
-
2007
- 2007-05-08 US US11/800,860 patent/US7528111B2/en active Active
- 2007-05-10 WO PCT/US2007/068631 patent/WO2007134147A2/en active Application Filing
- 2007-05-10 EP EP07797408A patent/EP2018181A2/en not_active Withdrawn
- 2007-05-10 JP JP2009511167A patent/JP2009536968A/en active Pending
- 2007-05-10 PE PE2007000565A patent/PE20080092A1/en not_active Application Discontinuation
- 2007-05-11 AR ARP070102048A patent/AR060897A1/en not_active Application Discontinuation
- 2007-05-11 TW TW096116968A patent/TW200812612A/en unknown
-
2008
- 2008-11-03 NO NO20084579A patent/NO20084579L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2009536968A (en) | 2009-10-22 |
PE20080092A1 (en) | 2008-02-11 |
EP2018181A2 (en) | 2009-01-28 |
US20080019999A1 (en) | 2008-01-24 |
AR060897A1 (en) | 2008-07-23 |
US7528111B2 (en) | 2009-05-05 |
TW200812612A (en) | 2008-03-16 |
WO2007134147A3 (en) | 2008-02-14 |
WO2007134147A2 (en) | 2007-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018098365A3 (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
MX2018010586A (en) | Sting activating nanovaccine for immunotherapy. | |
CY1118105T1 (en) | VASCULAR USE OF CUTTY STEM CELLS | |
NO20064388L (en) | Casein-derived peptides and therapeutic uses thereof | |
NO20092522L (en) | Compositions and Methods for Treating Cancer with Cupredoxins and CPG Rich DNA | |
WO2008103947A3 (en) | Activation of human antigen-presenting cells through clec-6 | |
EA201000644A1 (en) | ANTIBODIES FOR THE TREATMENT AND PREVENTION OF THE ALZGEIMER'S DISEASE AND THEIR APPLICATION | |
UA99659C2 (en) | Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof | |
AU2009326524A8 (en) | Use of Flt3 ligand for strengthening immune responses in RNA immunization | |
MX343633B (en) | Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them. | |
WO2009015842A3 (en) | Novel immunogenic epitopes for immunotherapy | |
MX2009010800A (en) | Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof. | |
EP3741846A3 (en) | Human betacoronavirus lineage c and identification of n-terminal dipeptidyl peptidase as its virus receptor | |
WO2009070294A3 (en) | Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof | |
NO20084396L (en) | combination therapy | |
MX2007012222A (en) | Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules. | |
WO2011071574A3 (en) | Monoclonal antibodies against glycoprotein of ebola sudan boniface virus | |
WO2014071402A8 (en) | Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions | |
WO2011035205A3 (en) | Antibodies against candida, collections thereof and methods of use | |
WO2006023598A3 (en) | Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer | |
WO2009135199A3 (en) | Vaccine compositions and methods | |
WO2012047267A3 (en) | Polyvalent immunogen | |
NO20084579L (en) | Procedure for Vaccination of Individuals Receiving Immunomodulatory Therapy | |
ZA200900816B (en) | CD4-receptor-derived peptides and method for the preparation thereof | |
WO2010057647A3 (en) | Methods and compositions for the diagnosis and treatment of diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |